Pal-AHK
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A palmitoylated tripeptide marketed in cosmetic serums for skin collagen stimulation and hair growth. The case rests almost entirely on cell-culture and mechanism studies in fibroblasts and dermal papilla cells, with no meaningful human data. There is essentially no human safety data, so its long-term profile is unknown. It is not an FDA-approved drug, sold as a cosmetic ingredient or unregulated research-grade product, with no role in clinical practice.
Read Full recordStudied uses & evidence
Studied uses(6)
Stimulation of collagen type I synthesis in fibroblasts
SpeculativeCollagen stimulation is documented for the related peptide GHK-Cu, not directly tested for Pal-AHK.
Hair follicle elongation and dermal papilla cell proliferation
SpeculativeSingle in vitro study using AHK-Cu (not Pal-AHK) in human follicle organ culture.
Anti-apoptotic activity in dermal papilla cells
SpeculativeOne cell-culture study; the main apoptosis assay (flow cytometry) was not statistically significant.
Evidence limits
- Evidence Level
- Preclinical
All evidence for Pal-AHK derives from in vitro cell culture studies on the parent AHK tripeptide and its copper complex AHK-Cu. The key mechanistic study is Pyo et al. 2007 on AHK-Cu and hair follicle growth, conducted at Seoul National University using ex vivo human hair follicles and cultured dermal papilla cells. No randomized controlled trials, no prospective cohort studies, and no clinical efficacy trials have been conducted with Pal-AHK in human subjects. The cited CIR assessment does not evaluate Pal-AHK. The clinical evidence gap is significant — most marketing claims for Pal-AHK are extrapolated from in vitro data or from studies on related but distinct palmitoyl peptides (Pal-GHK, pal-KTTKS).
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
No human clinical efficacy data
HighLocal skin irritation and sensitization
LowCopper toxicity risk when combined with copper supplements or AHK-Cu
TheoreticalFormulation instability with certain active ingredients
LowUnknown long-term safety profile
ModeratePregnancy and lactation safety unknown
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.